Compare
Fate Therapeutics Inc vs DBV Technologies S.A. vs Curis Inc vs Prime Medicine, Inc.
| Latest fiscal year | Fate Therapeutics Inc FATE | DBV Technologies S.A. DBVT | Curis Inc CRIS | Prime Medicine, Inc. PRME |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $6.65M | $5.64M | $9.44M | $4.63M |
| Revenue growth (YoY) | -51.2% | +35.8% | -13.4% | +55.3% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/m | n/m | -60.5% | n/m |
| Net margin | n/m | n/m | -80.3% | n/m |
| Net income | -$136.31M | -$146.95M | -$7.58M | -$201.14M |
| EPS (Diluted) | -$1.15 | -$1.05 | -$0.58 | -$1.35 |
| Operating cash flow | -$106.08M | -$121.18M | -$27.20M | -$162.56M |
| Free cash flow | -$112.04M | -$121.71M | n/a | -$167.09M |
| Cash & equivalents | $46.63M | $194.17M | $5.06M | $63.03M |
| Total assets | $318.94M | $233.72M | $19.97M | $342.73M |
| Total liabilities | n/a | $64.95M | $14.50M | $221.87M |
| Shareholders' equity | $207.18M | $168.77M | $5.46M | $120.87M |
| Return on year-end equity | -65.8% | -87.1% | -138.8% | -166.4% |
| Shares outstanding | 115.36M | n/a | 12.93M | 180.51M |
Revenue, most recent five fiscal years
| Fiscal year | Fate Therapeutics Inc | DBV Technologies S.A. | Curis Inc | Prime Medicine, Inc. |
|---|---|---|---|---|
| Latest | $6.65M Ended 2025-12-31 | $5.64M Ended 2025-12-31 | $9.44M Ended 2025-12-31 | $4.63M Ended 2025-12-31 |
| 1 year earlier | $13.63M Ended 2024-12-31 | $4.15M Ended 2024-12-31 | $10.91M Ended 2024-12-31 | $2.98M Ended 2024-12-31 |
| 2 years earlier | $63.53M Ended 2023-12-31 | $15.73M Ended 2023-12-31 | $10.02M Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | $96.30M Ended 2022-12-31 | $4.84M Ended 2022-12-31 | $10.16M Ended 2022-12-31 | $0 Ended 2022-12-31 |
| 4 years earlier | $55.85M Ended 2021-12-31 | $5.71M Ended 2021-12-31 | $10.65M Ended 2021-12-31 | $0 Ended 2021-12-31 |